Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU

Y Takahashi, M Mai, H Nakazato - Anticancer research, 2005 - ar.iiarjournals.org
Purpose: Immunochemotherapy using PSK, used as postoperative adjuvant chemotherapy
for colorectal cancer in Japan, is a treatment that depends on the immunocompetence of the …

Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant …

T Mitomi, S Tsuchiya, N Iijima, K Aso… - Gan to Kagaku ryoho …, 1989 - europepmc.org
To evaluate of adjuvant immunochemotherapy with PSK in curatively resected colorectal
cancer, randomized controlled study by 35 institutions in Kanagawa prefecture was …

Randomized, controlled study on adjuvant immunochemotherapy with PSK® in curatively resected colorectal cancer

T Mitomi, S Tsuchiya, N Iijima, K Aso… - Diseases of the Colon …, 1992 - journals.lww.com
A randomized, controlled trial of adjuvant immunochemotherapy with PSK (R)(Kureha
Chemical Industry Co., Tokyo, Japan) in curatively resected colorectal cancer was studied in …

Clinical effect of postoperative adjuvant immunochemotherapy with the FT-207 suppository and PSK in colorectal cancer patients. Colorectal Cancer Chemotherapy …

S Takashima, Y Kinami, I Miyazaki - Gan to Kagaku ryoho. Cancer & …, 1988 - europepmc.org
For a period of about three years from September 1980, a randomized controlled study was
performed on colo-rectal cancer patients who had undergone an absolute curative …

A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines

K Koda, M Miyazaki, H Sarashina… - International …, 2003 - spandidos-publications.com
Postoperative adjuvant chemotherapy reportedly improves advanced colorectal cancer
patients' survival, however, it is necessary to assess what regimens are useful. Doxifluridine …

Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival

Y Munemoto, Y Iida, J Abe, H Saito… - International …, 2002 - spandidos-publications.com
We examined the relationship between host as well as tumor factors and postoperative
survival rate in patients who received combination therapy of mitomycin C+ fluoropyrimidine …

Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer

T Sakai, Y Yamashita, T Maekawa… - Cancer biotherapy & …, 2008 - liebertpub.com
Long-term survival, which extends beyond 5 years, is a desired outcome for colorectal
cancer patients. In the present study, we retrospectively compared the 10-year overall …

Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor

Y Munemoto, Y Iida, K Ohata, H Saito… - Oncology …, 2004 - spandidos-publications.com
To identify responders when protein-bound polysaccharide (PSK) is used in adjuvant
immunochemotherapy after curative resection of colorectal cancers, we examined the host …

[HTML][HTML] Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer

S Ohwada, Y Morishita - British journal of cancer, 2004 - nature.com
We thank Dr C Alliot for his comments and critique in the editorial accompanying our article
(Ohwada et al, 2004). Regarding the choice of the control arm, we agree that the standard …

Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum levels of glycoproteins and HLA antigens as prognostic indicators

K Ogoshi, T Mitomi - Nihon Geka Gakkai Zasshi, 1989 - europepmc.org
This study was carried out to evaluate whether the preoperative levels of serum
glycoproteins (CEA, SCC, TPA, IAP, ACT, ASP and sialic acid) and HLA antigens (class I …